Navigation Links
NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
Date:12/12/2010

at the Institut Jules Bordet in Brussels, Belgium.  "The high confirmed objective response rate continues to show that NKTR-102 is one of the most active single agents in this disease.  This is particularly evident given the number of patients with dramatic reduction in lung and liver metastases."

The confirmed ORR was maintained in poor prognosis and heavily pre-treated subsets within the study, including patients previously treated with anthracycline/taxane/capecitabine: 33% (5/15); patients with metastatic triple-negative breast cancer: 39% (7/18); and patients with visceral disease: 29% (17/58).  As of October 26, 2010, preliminary median progression-free survival (PFS) for all patients was 20 weeks. [Efficacy Tables, Figures A - C]

"We are in critical need of effective new therapeutic options whose mechanism of action is different from those already available for women with metastatic breast cancer," continued Dr. Awada.  "This is especially true for those patients whose disease has progressed despite treatment with anthracyclines and taxanes.  NKTR-102 is emerging as an important investigational treatment in metastatic breast cancer and has the potential to be the first topoisomerase 1 inhibitor in this disease.  NKTR-102 should enter Phase 3 clinical studies as quickly as possible."

Patients treated in the single-agent NKTR-102 study had a median of two lines of prior cytotoxic treatments for metastatic disease.  Seventy-three percent (51/70) of the patients received neoadjuvant and/or adjuvant therapy and 87% (61/70) had visceral disease.  

"NKTR-102 is quickly emerging as a very important potential new drug in the fight against cancer," said Lorianne Masuoka, M.D., Senior Vice President and Chief Medical Officer.  "The drug has consistently high response rates as a single-agent in multiple Phase 1 and 2 clinical studies to-date, including our study in platinum-resistant ova
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
2. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
3. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
4. Significant Anti-Tumor Activity of NKTR-102 in Patients With Refractory Solid Tumors; Interim Data Published in ASCO 2008 Proceedings
5. Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting
6. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
7. NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition In Multiple Preclinical Tumor Models
8. Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
9. Phase 2 Data Presented at the 52nd Annual Meeting of the American Society of Hematology Demonstrates Promising Efficacy of KRX-0401 (Perifosine) in the Treatment of Advanced Leukemia, Lymphoma and Multiple Myeloma
10. Halozymes rHuPH20 With Recombinant Human Insulin Demonstrates Glycemic Control Comparable to Lispro
11. Pevions Breakthrough Candida Vaccine Demonstrates Safety and Immunogenicity in Phase I Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... Calif. , Oct. 1, 2014  Varian Medical ... it will report results for the fourth quarter of ... on Wednesday, October 22, 2014.  The news release will ... parties at 2:00 p.m. PT.  The news release and ... available on the company website at: www.varian.com/investor .  ...
(Date:10/1/2014)... , Oct. 1, 2014 Quantum ... scaling volume production of photoactive quantum dots for ... . While offering numerous advantages for solar power ... large quantities of quantum dots with which to ... kept them from commercial utilization and acceptance. The ...
(Date:10/1/2014)... FREMONT, Calif. , Oct. 1, 2014 ... ARDX ), a clinical-stage biopharmaceutical company focused ... announced positive results from its 371 patient ... patients with constipation-predominant irritable bowel syndrome (IBS-C).  ... and clinically meaningful improvement in IBS-C symptoms ...
Breaking Medicine Technology:Varian Medical Systems Schedules Fourth Quarter FY2014 News Release and Conference Call 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 2Quantum Materials Scaling Up Photoactive Quantum Dot Production for Solar Power Generation 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 2Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 3Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 4Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 5Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients 6
(Date:10/1/2014)... 01, 2014 Marriagelifeinsurance.com has released ... insurance for retired couples. , Senior citizens can ... security for their loved ones. A joint policy is ... persons pass away. , Life insurance can be ... insurance can even be purchased online, as the application ...
(Date:10/1/2014)... October 01, 2014 Bedros Keuilian is ... Boot Camp fitness boot camps, he’s also considered the ... , with sold out business summits, a line of ... consultant to a recent Spike TV reality show to ... now is the time for personal trainers and fitness ...
(Date:10/1/2014)... (PRWEB) October 01, 2014 First Warning ... abnormal circadian cellular changes throughout the body, announced the ... to better address the company’s breadth of upcoming product ... breast cancer screening technology. , “Our initial focus will ... system which detects abnormal circadian cellular changes over time,” ...
(Date:10/1/2014)... October 01, 2014 T.E.N., ... and relationship-marketing firm, announced today the nominees ... and Project of the Year Awards for ... representing organizations in financial services, commercial, health ... technology endeavors that address key issues in ...
(Date:10/1/2014)... MO (PRWEB) October 01, 2014 Join the ... Castlewood Eating Disorder Treatment Center’s first ever charity golf tournament ... for people with eating disorders who cannot afford treatment. The ... Golf Club in Eureka, Mo. , The day-long event ... noon. A reception and award dinner will begin at 5 ...
Breaking Medicine News(10 mins):Health News:Elderly Life Insurance - Find Life Insurance for Retired Couples! 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 2Health News:Bedros Keuilian Shares Tips on Selling Personal Training for the Holidays 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 2Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 3Health News:First Warning Systems Changes Name to Cyrcadia Health to Better Reflect Core Competency and Goals of Company 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 2Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 3Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 4Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 5Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 6Health News:T.E.N. Announces Nominees for the 2014 ISE® North America Awards; People’s Choice Award voting now open to industry at large 7Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 2Health News:Project HEAL Benefit Golf Tournament Gaining Momentum 3
... HealthDay Reporter , TUESDAY, Jan. 18 (HealthDay News) ... might have another use: clearing arterial blockages in the ... research involving 19 stroke patients, doctors say this experimental ... patients for whom other clot-removal methods didn,t work. ...
... health may contribute to a healthy respiratory system, according ... . A new study suggests that periodontal disease may ... obstructive pulmonary disease (COPD) and pneumonia. These infections, which ... inhaled into the lower respiratory tract, can be severely ...
... advise about alcohol consumption?" was recently published by Maurizio Ponz ... argues that the message of health benefits of moderate drinking ... the general population." His reasons included (1) many people ... of wine, beer or spirits, and alcohol metabolism may differ ...
... 18 (HealthDay News) -- Women with polycystic ovary syndrome (PCOS) ... many consumer products than other women, a new study suggests. ... products, food and drink packaging and even dental materials. PCOS, ... characterized by excessive production of male sex hormones (androgens). PCOS ...
... XX, 2010) Thea Friedman, M.D., associate scientist and ... Cancer Center at Hackensack University Medical Center was recently ... (NIH-NCI) RO1 research grant to improve allogeneic blood ... grant provides $2 million in funding over the next ...
... is available in French . Montreal, ... in biology at Universit du Qubec Montral (UQAM), supported ... Elsy Edouard, UQAM, Department of Biological Sciences and BIOMED ... B-cell acute lymphocytic leukemia, a disease that occurs most commonly ...
Cached Medicine News:Health News:Stents Show Promise in Treating Brain Blockages 2Health News:Stents Show Promise in Treating Brain Blockages 3Health News:Healthy gums may lead to healthy lungs 2Health News:Critique 029: What should we advise about alcohol consumption? A debate amongst scientists 2Health News:Ovarian Cyst Syndrome May Raise Health Risks from Plastics Chemical 2Health News:Oncology basic research director at John Theurer Cancer Center continues transplantation research 2Health News:Discovery of a gene associated with a leukemia mostly affecting children 2
... Normal and Abnormal Control ... of vWF, D-dimer and ... STA© Analyzers. For use ... (#0518),STA© LIATEST© D-DI (#0515) ...
CRP Full Range (0.1-160mg/l)...
Inquire...
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Medicine Products: